Recent YSCC Discoveries

24 Yale Medicine dermatologists were named "Top Doctors" for 2026 by Connecticut Magazine.

12 Yale Medicine neurologists have been named "Top Doctors" for 2026 by Connecticut Magazine.

The biotech company Arvinas was originally founded based on pioneering research from Yale chemist Craig Crews into PROTAC protein degraders.

Seventeen faculty members of the Department of Pathology are among the “Top Doctors,” according to Connecticut Magazine’s 2026 list.

While scientists have identified hundreds of different genes that are associated with autism, a new Yale-led study suggests that the specific genes may be less important than the pathway they take to the brain.

Seventeen Yale Ob/Gyn faculty members have been recognized in Connecticut Magazine's 2026 “Top Doctors” edition.

Yale Cancer Center faculty and trainees joined over 22,000 cancer researchers from around the world to share the latest advances in cancer science and medicine earlier this week in San Diego for the 117th American Association for Cancer Research (AACR) annual meeting.

David Stitelman, MD, has received funding from the Cystic Fibrosis Research Institute to advance his collaborative research on a novel fetal therapy approach for cystic fibrosis. Working with colleagues across pediatric pulmonology, biomedical engineering, and gene editing, his team is developing nanoparticle-based strategies to deliver gene therapies before birth—aimed at preventing organ damage that begins in utero. By combining mRNA delivery and high-fidelity gene editing, this work has the potential to move toward a one-time treatment for cystic fibrosis and establish a new paradigm for treating genetic diseases before birth.

The iPSC Neurocore of the Department of Neuroscience, led by Tanina Arab, PhD, and the STEM Cell core of the STEM Cell Center, led by Caihong Qiu, PhD, are among the recipients.